Markets BTIG ups Eidos Therapeutics PT to $56 from $38 BTIG raised its price target for Eidos Therapeutics (NASDAQ:EIDX) to $56 from $38 after a committee of the board unanimously rejected a share exchange offer from its parent company, BridgeBio Pharma, (NASDAQ:BBIO) to... September 13, 2019